The shrinking return on investment for Nordic innovation
Nordic biopharma innovation outpaces commercialisation as regional biotechs struggle to raise the capital needed to upscale.
Nordic biopharma innovation outpaces commercialisation as regional biotechs struggle to raise the capital needed to upscale.